Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy

Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We aimed to identify anticoagulation management strategies and evaluate bleeding and thrombosis rates associated with each approach. A retrospective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and thrombolysis 2021-08, Vol.52 (2), p.590-596
Hauptverfasser:	Livneh, Nir, Braeken, Dionne, Drozdinsky, Genady, Gafter-Gvili, Anat, Seelig, Jaap, Rozovski, Uri, Berger, Tamar, Raanani, Pia, Falanga, Anna, ten Cate, Hugo, Spectre, Galia, Leader, Avi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anemia Anticoagulants - adverse effects Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Bleeding Cardiac arrhythmia Cardiology Fibrillation Hematologic Neoplasms - complications Hematologic Neoplasms - drug therapy Hematology Hemorrhage - chemically induced Humans Malignancy Medicine Medicine & Public Health Multivariate analysis Patients Platelets Retrospective Studies Thrombocytopenia Thrombocytopenia - chemically induced Thrombocytopenia - drug therapy Thromboembolism Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We aimed to identify anticoagulation management strategies and evaluate bleeding and thrombosis rates associated with each approach. A retrospective cohort study in Israel and the Netherlands was conducted. Patients with hematological malignancy and atrial fibrillation were indexed when platelets were
ISSN:	0929-5305 1573-742X
DOI:	10.1007/s11239-021-02393-8